On May 2, 2026, the Supreme Court will hear a case involving Danco Laboratories and Louisiana regarding the abortion pill mifepristone. Two companies that produce the drug are seeking to halt a ruling from the U.S. Court of Appeals for the 5th Circuit.
The appeals court's decision reinstated certain restrictions that could impact access to mifepristone, prompting the manufacturers to appeal to the highest court for relief.
This case underscores the continuing legal battles over reproductive rights and the regulation of abortion medications in the United States.